Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives
US5972885A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 21, 1995 |
| Grant date | Oct 26, 1999 |
| Priority date | — |
| Expiry date | Dec 21, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising recombinant coagulation factor VIII and use thereof for manufacture of a medicament for treating haemophilia is provided. The formulation comprises a highly purified recombinant coagulation factor VIII in a concentration of at least 1000 IU/ml, which gives surprisingly high levels of active factor VIII in the blood stream after subcutaneous, intramuscular or intradermal administration. The formulation is intended for treatment of haemophilia by subcutaneous, intramuscular or intradermal administration. The recombinant factor VIII is preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.